Immutep Limited (IMMP)
| Market Cap | 234.43M |
| Revenue (ttm) | 11.38M |
| Net Income (ttm) | -9.29M |
| Shares Out | 64.87M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $3.48 |
| Previous Close | $3.53 |
| Change ($) | -0.05 |
| Change (%) | -1.42% |
| Day's Open | 3.52 |
| Day's Range | 3.47 - 3.53 |
| Day's Volume | 153,948 |
| 52-Week Range | 1.22 - 7.95 |
Immutep Limited (NASDAQ: IMMP) has completed all the necessary steps with the FDA and has received institutional review board approval to commence its Phase 2b TACTI-003 trials in the U.S. Patient recru...
Immutep (NASDAQ: IMMP) will begin a Phase 1 trial to evaluate its lead product candidate, eftilagimod alpha (efti or IMP321), in conjunction with chemotherapy and anti-PD-1 therapy. The trial, named INS...
Reddit penny stocks are full of risk and reward, which is why $100 won't hurt you, but it can reward you handsomely. The post 7 Reddit Penny Stocks to Buy if You Have $100 to Spare appeared first on Inv...
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
SYDNEY, AUSTRALIA, June 04, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...
SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer ...
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors. The tri...
SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer an...
Immutep Limited (NASDAQ: IMMP) has announced that data from its TACTI-002 and INSIGHT-004 studies have been published in abstracts for the American Society of Clinical Oncology's 2021 Annual Meeting. Da...
Are these the top penny stocks to buy in 2021? Take a look and decide for yourself The post Top Penny Stocks to Buy Now?
These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...
Sydney, AUSTRALIA, May 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatment...
SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer an...
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from t...
Investors liked the company's latest regulatory update.
Vericity (VERY) stock is on the rise Thursday morning despite a lack of news for the company in what could be a mix-up for investors. The post VERY Stock: Is a VERY Big Mix-Up Causing Vericity to Skyroc...
Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia....
IMMP stock is getting a boost in Thursday trading after European regulators gave one of its cancer antibodies a key patent. The post IMMP Stock: The Big Patent News Boosting Immutep Today appeared first...
Sydney, AUSTRALIA, April 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...
Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer,...
Immutep was one of the Benzinga Biotech Small Cap Conference held virtually on March 24 & 25, 2021. The information contained in this article in no way represents investment advice or opinion on the par...
Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...
Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.
Sydney, AUSTRALIA, March 17, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...
Immutep (NASDAQ: IMMP) announces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1s...
Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...
Follows positive efficacy and safety review Follows positive efficacy and safety review
Highlights
Immutep's Collaboration and Exclusive License with GSK Remains in Place Immutep's Collaboration and Exclusive License with GSK Remains in Place
Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is ple...
Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer a...
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for ...
JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reported ...
Shares of IMMP stock are taking off on Thursday after the firm's China-based partner announced a new breast cancer treatment trial in 2021. The post IMMP Stock: Why Immutep Stock Is Up 225% So Far Today...
Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metast...
Shares of Immumetp Ltd., an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer.
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pl...
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is plea...
SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “...
Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on NASDAQ ...
Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release
SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer a...
SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is ple...
SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement...
SYDNEY, Australia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today ...
SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer a...
SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer a...
SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poste...
SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data w...
SYDNEY, Australia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner...
SYDNEY, Australia, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...
About IMMP
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evalu... [Read more...]
| Industry Biotechnology | |
| CEO Marc Voigt | Country Australia |
| Stock Exchange NASDAQ | Ticker Symbol IMMP |
Financial Performance
In 2020, Immutep's revenue was 16.50 million, an increase of 120.31% compared to the previous year's 7.49 million. Losses were -13.47 million, -26.58% less than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for Immutep stock is "Buy." The 12-month stock price forecast is 8.51, which is an increase of 144.54% from the latest price.